Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital London. He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials and is the current Vice President (Europe & Middle East) of the International Society for Cell & GeneTherapy.
He has over 20 years’ experience in adoptive immunotherapy of cancer and has focussed on the role of the innate immune responses; especially the role of natural killer (NK) cells.
He has focussed particularly on translational research and established the first academic GMP facility in the UK for the production of human cells as medicines in 2003. This GMP facility now produces somatic cell medicines, gene therapies and tissue engineered products. The first cellular medicine manufactured in this facility was Professor Lowdell’s own adoptive NK cell therapy product, Tumour-primed NK cells, and, during the UK clinical trial he led the technology transfer of this into three commercial CMOs in the US and was the chief scientific officer for the US clinical trial.
His newly refurbished ATMP GMP suite at RFH/UCL consists of 12 state-of-the-art manufacturing labs and over 20 staff supporting multiple academic and commercial trials of somatic cell and tissue engineered therapies whilst continuing his development of NK-based immunotherapies. Most recently he has founded InmuneBio Inc with Dr RJ Tesi and David Moss to develop an “off-the-shelf” iteration of the tumour-primed NK concept and the first clinical trials will open in the UK in Q4 2018.
Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. Recently he was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA including Autolus Ltd, Achilles Therapeutics Ltd, Cell Medica Ltd, InmuneBio Inc, Novamune Ltd and NWBio Therapeutics.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.